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Transformation of chicken fibroblasts in vitro by Rous Sarcoma Virus represents a model of cancer in which a single oncogene, viral src,
uniformly and rapidly transforms primary cells in culture. We experimentally surveyed the transcriptional program affected by Rous Sarcoma
Virus (RSV) in primary culture of chicken embryo fibroblasts. As a control, we used cells infected with non-transforming RSV mutant td106, in
which the src gene was deleted. Using Affymetrix GeneChip® Chicken Genome Arrays, we report 811 genes that were modulated more than 2.5
fold in the virus transformed cells. Among these, 409 genes were induced and 402 genes were repressed by viral src. From the repertoire of
modulated genes, we selected 20 genes that were robustly changed. We then validated and quantified the transcriptional changes of most of the 20
selected genes by real-time PCR. The set of strongly induced genes contains vasoactive intestinal polypeptide, MAP kinase phosphatase 2 and
follistatin, among others. The set of strongly repressed genes contains TGF beta 3, TGF beta-induced gene, and deiodinase. The function of
several robustly modulated genes sheds new light on the molecular mechanism of oncogenic transformation.
© 2007 Elsevier Inc. All rights reserved.Keywords: Avian sarcoma; Schmidt-Ruppin strain of RSV; src oncogene; Protein-tyrosine kinase; Vasoactive intestinal polypeptide; MAP kinase phosphatase 2;
FollistatinIntroduction
Transformation of primary chicken fibroblasts (CEFs) in
vitro by Rous Sarcoma Virus (RSV) continues to represent an
important experimental model of cancer (Martin, 2004). The
transforming gene of RSV, the viral src oncogene (v-src), is an
activated and overexpressed protein-tyrosine kinase responsible
for a number of molecular events that govern rapid and dramatic
phenotypic changes observed in transformed host cells (Jove
and Hanafusa, 1987; Blume-Jensen and Hunter, 2001; Darnell,
2002; Frame, 2002). Transformation-specific changes in cell
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doi:10.1016/j.virol.2007.03.026growth are accompanied by changes in gene expression. In
the past, a number of laboratories reported identification of
individual genes that were either induced or repressed by the
v-src oncogene at the level of transcription (Howard et al.,
1978; Hendricks and Weintraub, 1981; Fagan et al., 1981;
Sugano et al., 1987; Bedard et al., 1987; Jahner and Hunter,
1991; Dehbi and Bedard, 1992; Herault et al., 1992; Frankfort
and Gelman, 1995). With the recent completion of the chicken
genome sequence (Wallis et al., 2004; Hillier et al., 2004) and
the subsequent availability of Affymetrix GeneChip® Chicken
Genome Arrays that represent the full complement of the
genome, we experimentally surveyed the transcriptional
program affected by RSV transformation in the syngeneic
system of Schmidt-Ruppin strain of RSV (RSV-SR) and
primary culture of CEFs. As a control, we used CEFs infected
with non-transforming RSV (td106) derived from the Schmidt-
Ruppin strain of RSV in which the src gene was deleted (Wang
11Rapid Communicationet al., 1984). Thus, the isogenic pair of viruses differed only in
the src gene, but not in the replicative genes, allowing one to
score for transcripts relevant for src transformation. The
rationale for the global analysis of transcriptional changes
caused by v-src was to provide better understanding of the
mechanism of transformation, taking advantage of a cancer
model in which a single oncogene uniformly and rapidly
transforms primary cells in culture (Brugge and Erikson, 1977).
Using GeneChip® Chicken Genome Arrays that cover
32,773 transcripts corresponding to 28,418 predicted genes
from the Ensembl annotation of the complete genome, we report
409 genes that are induced and 402 genes that are repressed at
the level of transcription by v-src. From the repertoire of
modulated genes, we selected 20 genes (10 induced and 10
repressed) that were robustly changed by v-src in the screen of
Affymetrix DNA arrays. We then validated and quantified the
transcriptional changes of most of the 20 selected genes by real-
time PCR using array-independent sets of primer oligos and
new preparations of RNA. The function of several robustly
induced and repressed genes sheds new light on the molecular
mechanism of oncogenic transformation.
Results and discussion
Identification of v-src-modulated genes
Analysis of GeneChip® Chicken Genome Arrays probed
with RSV-SR wild type and RSV-SR-td106 mutant derived
probes revealed that circa 10% of transcripts were changed.
From 28,418 chicken genes investigated in the screen, 17,868
were detected at least once in RSV-SR or RSV-SR-td106 mutant
screens. Among the detected genes, 1602 were induced and
1386 were repressed in v-src transformed cells. These changes
were considered significant as they had a p-value of 0.05 or
less. When a filter of two moderately stringent criteria was
applied to the data, namely that the changes had to be more than
2.5 fold (linear, in either direction) and the p-value had to be
less than 0.05, the number of modulated transcripts decreased
by more than 3 fold to 811. Among the selected transcripts, 409
were induced and 402 were repressed by v-src (see Figure A
representing a heat map of hierarchical clustering and Table A
listing all 811 modulated sequences in Supplementary data).
This set of data contained several genes that had been
previously documented as v-src-modulated genes: urokinase-
type plasminogen activator, gene for glucose transporter
protein, and nephroblastoma overexpressed gene (Leslie et al.,
1990; White et al., 1991; Scholz et al., 1996).
Validating selected transcripts by RT-PCR
We chose 20 robustly modulated genes from the “stringent
set” of 811 modulated transcripts for further analysis. Among
these 20 genes, 10 were induced and 10 repressed (Table 1). We
isolated new RNAs from independent RSV-SR transformed and
RSV-SR-td106 infected CEFs and generated the array-inde-
pendent set of primer oligos to validate and quantify the
changes by another technique, real-time PCR (RT-PCR). Usinga housekeeping transcript, GAPDH, as a control for quantifica-
tion and documenting the quality of each of the amplified
products by melting curve analysis, we confirmed most (17 out
of 20) of the transcriptional changes identified in the array
screen. The changes scored by the GeneChip® Chicken
Genome Array screen were in most cases larger than the
changes measured by RT-PCR, even when the same RNA was
used for the assays. This is often the case because of the intrinsic
difficulty in setting the right background for the array analysis,
especially with low signals from un-induced transcripts
(personal communication from T. Hunter).
Gene ontology analysis
In an effort to determine trends in the regulation of classes of
genes in response to v-src transformation, lists of Affymetrix
Probe Set IDs for 811 genes that are significantly increased or
significantly decreased (Table A) were submitted separately to
DAVID 2006 (http://niaid.abcc.ncifcrf.gov/home.jsp). DAVID
is a program that facilitates the transition from genome-scale
data sets to biological meaning (Dennis et al., 2003). The
software identified 41 and 47 terms that are significantly over-
represented in a functional annotation chart of the genes with
increased or decreased expression, respectively. The most
significantly over-represented terms for the genes with
increased expression included many related to phosphatase
activity, proto-oncogenes, nuclear proteins, and DNA binding.
In contrast, the most significantly over-represented terms for the
genes with decreased expression included several related to the
cytoskeleton, extracellular matrix, cell adhesion, endoplasmic
reticulum, signal peptides, and glycoproteins. The Probe Set
IDs associated with each of these terms are presented in
Supplementary Table B. The terms associated with down-
regulated genes seem to connote normal cellular growth,
attachment, and secretion of regulatory factors, while those
associated with up-regulated genes hint at abnormal DNA
replication. One stand-out feature is the number of phosphatases
that are up-regulated in the transformed cells.
Integrating and interpreting the transcriptional fingerprint of
v-src in CEFs
Two other approaches were elected to analyze the data
globally, focusing on the signaling system. In the first approach,
we used the most recent version (2.1) of GenMAPP (Gene
MicroArray Pathway Profiler) and MAPPFinder, two software
packages from Gladstone Institutes of the University of
California at San Francisco (www.genmap.org) to analyze
changes in the outcomes of signaling pathways caused by v-src-
modulated genes. We uploaded 2988 transcripts that were
changed by v-src, with p-values no higher than 0.05, into the
GenMAPP program and viewed the data on pathway profiles
(MAPPFinder) that represent major biological pathways and
functional grouping of genes (Doniger et al., 2003). Several
signaling pathways, including TGF beta, MAP kinase, cell
cycle, and the kinin-kallikrein component of the complement
activation scored well in the GenMAPP analysis in terms of
Table 1
Transcripts modulated in RSV transformed chicken cells
Gene symbol Accession # MW Gene name Array (n=3) RT-PCR (n=2)
RSV (v-src) induced genes a
PLAU NM_205443 49 Plasminogen activator, urokinase 196±69 42±11
VIP NM_205366 22 Vasoactive intestinal peptide 124±60 54±0.5
LOC423497 XM_421400 353 AHNAK 1 and 2 related protein* 26±5 8±5
LOC421581 XM_419619 20 EMT organic cation transporter 3* 18±15 N.C.
LOC423769 XM_421641 65 Arachidonate 5-lipoxygenase* 13±6 7±3.5
LOC421692 XM_419729 86 cAMP-specific phosphodiesterase 7B* 10±5 10±1.5
FST NM_205200 38 Follistatin 9±5 4±0.5
LOC423890 XM_421754 75 Dual specificity phosphatase 5* 7±4 7±1.5
NES NM_205033 202 Nestin 7±1 1±0.2
MKP-2 NM_204838 41 MAP kinase phosphatase 2 6±2 26±15
RSV (v-src) repressed genes
NPC2 NM_001004393 21 Stathmin-like 45±52 2±0.2
NOV NM_205268 38 Nephroblastoma-overexpressed gene 42±39 18±15
TGFBI NM_205036 74 TGF beta-induced protein, 68 kDa 28±31 7±4
LOC418180 XM_416411 23 RAB, estrogen-regulated growth inhibitor* 18±8 2±0.3
LOC428711 XM_426269 61 Four and a half LIM domains 1 protein 15±1 3±0.5
DIO2 NM_204114 31 Deiodinase 15±6 5±1
C1QTNF3 XP_425002 34 C1q and TNF-related protein 3 13±6 3±0.5
CPEB1 XM_413713 80 Cytoplasmic polyadenylation element BP1 8±3 0.3±0.1
TFPI XM_421849 35 Tissue factor pathway inhibitor 5±2 3±1
TGFB3 NM_205454 47 TGF beta 3 5±0.8 5±2.5
“MW” represents molecular weight in kilodaltons of the unprocessed protein product calculated from the translated cDNA of the predicted gene product with the aid of
ExPASy tools.
N.C. stands for “not confirmed”. It applies to one transcript for which we could not obtain a single size DNA product with the real-time PCR, in spite of trying three sets
of primers spanning different regions of the sequence.
a v-src oncogene was up-regulated 265 (±45) fold in RSV-SR transformed CEF compared to CEF infected with the non-transforming derivative of RSV-SR td106
mutant. Since there is no v-src gene expressed in the control, non-transformed cells, the overexpression value for the v-src transcript reflects a comparison with the
endogenous level of c-src transcript. The value is derived from three independent experiments (n=3) in which chicken genome arrays were screened with cRNA
probes derived from independent sets of transformed and infected cells.
* denotes “similar” in most cases based on the annotation of the sequence provided by Affymetrix. For all the sequences, which we marked here with ‘*’ and
therefore termed as “similar” to knownmammalian genes, we performed BLASTP analysis and compared them to human proteins. The sequences were from 60 to 80%
identical over the main portions of proteins and most likely represent bona fide orthologs. However, a caution is advised as there are examples of avian-specific genes
that share a significant degree of sequence identity with mammalian genes but do not represent their orthologs, e.g., chicken yrk and human yes (Sudol et al., 1993).
12 Rapid Communicationintegrating from several to two dozen modulated genes into the
signaling schemes. However, the concerted action of changed
genes, in terms of activation or repression of the signaling
outcomes, was not apparent from this analysis. Therefore, we
decided to focus solely on the most robustly changed genes,
gathering published data for each one and systematically
integrating all of this information into a logical scheme.
Induced genes
After the v-src gene, which we found was overexpressed in
the RSV-SR-transformed cells on average 265 fold (compared
to cellular src (c-src) gene in RSV-SR-td106 infected CEFs),
the urokinase-type plasminogen activator (PLAU) was the
second most up-regulated gene (196 fold in the array and 42
fold by RT-PCR). Both the PLAU transcript and the protein
were previously shown to be elevated in RSV transformed
CEFs (Unkeless et al., 1973; Sudol, 1985; Leslie et al., 1990).
This enzyme was also implicated in the metastatic potential of
tumor cells (Ossowski and Reich, 1980) and the regulation of
fibronectin pathway matrix assembly (Monaghan-Benson and
McKeown-Longo, 2006).Vasoactive intestinal peptide (VIP) also belongs to the class
of genes that are robustly up-regulated by v-src (124 fold in the
arrays and 53 fold in the RT-PCR) in our screen. As this gene
was not known or even expected to be transcriptionally induced
in RSV transformed cells, we considered this finding interesting
and decided to validate this change further (see below). VIP is a
neuromodulator that regulates vasodilation, smooth muscle
relaxation and epithelial cell secretion in the intestine. A report
on the activation of c-src in cells treated with VIP (Koh, 1992)
and a recent study implicating VIP in anti-apoptotic signaling
(Sastry et al., 2006) could explain the role of this gene in the
enhancement and/or maintenance of oncogenic transformation.
The frequent occurrence of c-src activation in human colon
cancer (Bolen et al., 1987; Cartwright et al., 1990; Pories et al.,
1998) may be functionally linked to the normal expression of
intestinal VIP, which may act as a stimulator of src kinase
activity (Koh, 1992).
The LOC423497 transcript encodes a protein similar to the
human AHNAK (KIAA2019), a high molecular weight (ca.
700 kDa) phosphoprotein that was originally identified as a
product of a gene repressed in neuroblastoma cells (Shtivelman
et al., 1992; Komuro et al., 2004). One interesting feature of the
13Rapid CommunicationAHNAK protein is its differential distribution between nuclear
versus plasma membrane and cytoplasmic compartments.
The nuclear exclusion of AHNAK correlates with cell-to-cell
contacts in epithelial cells. The increased expression and the
resulting abnormal distribution of the AHNAK in v-src trans-
formed fibroblasts may contribute to the loss of contact in-
hibition (Haase, 2007).
The induction of transcript LOC423769, which encodes an
enzyme similar to human arachidonate 5-lipoxygenase
(ALOX5), resonates with an earlier study that documented
changes in arachidonic acid metabolism in RSV transformed
cells (Barker et al., 1989). The transcript is significantly up-
regulated; 13 fold in the array experiments and 7 fold in RT-
PCR assay. ALOX5 metabolizes arachidonic acid into bioactive
lipids, which are generally implicated in inflammation and
specifically in colon cancer risk (Goodman et al., 2004; Poole
et al., 2006). By promoting inflammation, the ALOX5 gene
may contribute to the process of tumor progression.
LOC421692 is a v-src induced transcript that is similar to
cAMP-specific 3,5-cyclic phosphodiesterase 7B (PDE7B).
PDEs hydrolize the second messengers, cyclic AMP and cyclic
GMP, to their corresponding mono-phosphates, affecting a wide
spectrum of intercellular events. Studying this particular
isoform of PDE in transformed cells and tumors in more detail
may uncover a new aspect of signaling by second messengers,
which is relevant for oncogenic transformation.
Follistatin (FST) is a small protein that was originally
identified by its ability to inhibit FSH (follicle-stimulating
hormone) release by binding to activins, the stimulators of FSH
secretion. Activins are members of the TGF beta superfamily of
ligands. The activins and their antagonist follistatin act as a
pleiotropic growth factor system that regulates cell growth and
apoptosis (Stove et al., 2004; Krneta et al., 2006). One possible
reason for the increase in follistatin levels in RSV transformed
cells could be to titrate out activins in order to keep the TGF
beta receptor activity low, eliminating its possible growth-
inhibiting signals. Decreased levels of TGF beta 3 and the TGF
beta-induced gene, TGFBI, both seen in RSV transformed cells,
further support this proposal. Moreover, a recent report showed
that follistatin is overexpressed in liver tumors and when
recombinant follistatin protein was added to normal or pre-
neoplastic hepatocytes in primary culture, it stimulated DNA
synthesis (Grusch et al., 2006). In the same system, addition of
activin repressed the synthesis of DNA. In short, follistatin may
promote growth of RSV transformed CEFs.
Dual specificity phosphatases (DUSPs) can target various
substrates and dephosphorylate them at serine/threonine and
tyrosine residues. DUSPs are known to inactivate MAP kinases
by dephosphorylating them at specific tyrosine and threonine
sites. Perhaps DUSP5 acts in concert with another gene
product induced by v-src: MAP kinase phosphatase 2 (MKP-
2). The increase in the expression of MAP kinase phosphatases
is in agreement with previous observations (Stofega et al.,
1997). In general, cells stably transformed by v-src show only
a modest elevation in ERK1/2 activity. However, there is a
more marked but transient increase in ERK1/2 activity when a
temperature sensitive mutant of v-src is reactivated. Further-more, v-src-transformed cells are resistant to ERK1/2 activa-
tion by TPA or serum. The elevated expression of MKP-2 and
DUSP5 could be a part of a negative feedback mechanism
which ensures that ERK1/2 activation is only transient (Stofega
et al., 1997).
Repressed genes
NOV (nephroblastoma overexpressed) was originally iso-
lated as a gene that was up-regulated in Myeloblastosis
Associated Virus-induced nephroblastomas in chickens (Joliot
et al., 1992; Martinerie et al., 1994). Similar to the PLAU gene,
NOV was also previously shown as a transcript that is
modulated by v-src in CEFs (Scholz et al., 1996). The NOV
(also known as CCN3) gene encodes a secreted protein that is
associated with the cellular matrix and promotes cell adhesion.
In terms of tumor progression, NOV appears to exhibit
suppressive effects in contrast to its related protein, known as
CCN (Bleau et al., 2005). Based on the current knowledge of
the NOV function in various cells (Lafont et al., 2005; Li et al.,
2006; Perbal, 2006), we suggest that the down-regulation of
NOV promotes anchorage-independent growth and migration
of RSV-SR-transformed CEFs.
Transforming growth factor beta-induced protein of 68 kDa
molecular weight (TGFBI) is one of the v-src repressed genes.
The TGFBI encodes a protein that is similar to fasciclin-like
adhesion protein (Kawamoto et al., 1998). The repression of this
gene product most likely contributes to the dramatic reduction
in adhesive properties of RSV transformed cells. The substantial
down-regulation (5–14 fold) of transforming growth factor beta
(TGFB3) itself may provide an additional mechanism that
ensures a low level of the TGFBI gene product.
Similar to TGFBI, the repression of “four and a half LIM
domain 1” protein (FHL1) should also promote non-anchored
growth. A recent study has identified FHL1 gene as a tumor
suppressor that acts downstream of src and CAS (focal adhesion
adaptor protein Crk-associated substrate) to block anchorage-
independent cell growth and migration (Shen et al., 2006). The
c-src is known to phosphorylate CAS, which in turn inhibits
FHL1 expression and promotes, to a certain degree, cell
migration and non-anchored growth. Analogous to the signaling
of c-src, the v-src must phosphorylate CAS quite efficiently to
block FHL1 expression and to fully enhance non-anchored
growth of RSV transformed CEFs. Consistent with this
reasoning, FHL1 was found as a gene suppressed in various
human tumors (Shen et al., 2006).
The type 2 deiodinase (DIO2) is a seleno-enzyme that
catalyzes the conversion of thyroid hormone 4 (thyroxine) to
thyroid hormone 3 (triiodothyronine) via deiodination. The
repression of this gene in RSV transformed CEFs could lead to
the decrease of endogenous triiodothyronine, thereby inhibiting
signals of its receptor, cellular erbA. This, in turn, should
abrogate inactivation of AP-1 transcription factor as shown
previously in chicken cells (Desbois et al., 1991a, 1991b). The
active AP-1, together with the up-regulated jun (see below),
could contribute in unison to signals that enhance cell growth,
inflammation and metastasis (Ozanne et al., 2007).
Fig. 1. Functional network of robustly induced (red) and repressed (blue)
transcripts and their interacting partners (black) in primary chicken cells
transformed by Rous Sarcoma Virus. By surveying the literature on the function
of each of the 20 gene products that were most dramatically changed in RSV
transformed CEFs, we propose a model of their concerted action of promoting
cellular transformation and tumor progression. Detailed study of individual
genes rather than computer-aided annotation of the genes and their networks was
employed to reveal functional outputs of changed transcripts, assuming that
changes in transcription corresponded to changes in the protein level. Out of the
20 genes modulated by v-src, 10 could be linked to promoting a cancer
phenotype based on their functional characteristics. These include: follistatin
(FST) that contributes to cell growth stimulation by titrating out activin(s)
(ACT) and keeping TGF beta receptor (TGFBR) signaling in “low gear”. The
low activity of TGFBR is also kept in check by decreased levels of TGF beta 3
(TGFB3). As a consequence, one of the TGF beta-induced genes (TGFBI) that
encodes an adhesion protein is down-regulated, contributing to the anchorage-
independent growth of transformed cells. Reduced levels of tissue factor
pathway inhibitor (TFPI), together with high levels of urokinase-type
plasminogen activator (PLAU), play a role in tumor metastasis. Up-regulated
arachidonate 5-lipoxygenase (ALOX5) should contribute to tumor development
and progression by promoting inflammation. Down-regulated type 2 deiodinase
(DIO2) would decrease the levels of endogenous triiodothyronine and indirectly
activate AP-1 transcription factor contributing to signals that enhance cell
growth, inflammation and metastasis. The role of four and half LIM domain
protein 1 (FHL1) in cell adhesion has been documented and the repression of
FHL1, which is regulated by src-phosphorylated CAS, promotes anchorage-
independent growth. Tumor suppressive action of nephroblastoma over-
expressed gene (NOV) is linked to the control of cell adhesion. The reduced
levels of NOV promote anchorage-independent growth. Induction of AHNAK,
a gene that encodes a large phosphoprotein, may also contribute to the loss of
contact inhibition. See the text for more detailed description of the scheme plus
relevant references.
14 Rapid CommunicationComplement 1q and tumor necrosis factor-related protein 3
(C1QTNF3) is not well characterized in terms of function, and
its role in transformation cannot be easily commented on.
In contrast to C1QTNF3, the down-regulation of tissue factor
pathway inhibitor gene (TFPI), which encodes a multivalent
Kunitz-type serine proteinase inhibitor, could be implicated in
the mechanism of transformation. TFPI regulates the extrinsic
pathways of blood coagulation. The protein is generally
expressed and secreted by vascular cells. Highly malignant
human tumors have low or undetectable expression of TFPI
compared to benign tumors, implicating the inhibitor in tumor
invasion and metastasis (Kondraganti et al., 2006). The activity
of TFPI is most likely exerted through plasmin-mediated matrix
remodeling. In this light, the acute malignancy of RSV-SR-
induced chicken tumors could be explained by the combined
action of down-regulated TFPI and up-regulated PLAU.
The model summarizing the concerted action of selected
genes that are modulated by v-src is presented in Fig. 1.
Validating the induction of the VIP transcript at the level of
protein
Since up-regulation of the VIP transcript in v-src trans-
formed CEF was substantial (ca. 50 fold), we decided to
validate its induction at the level of protein. In parallel, we also
performed pilot immuno-stainings of human colon and breast
cancer biopsies with src Tyr-416 phospho-specific and VIP
antibodies, hoping to see a correlation between the activated src
and VIP expression in tumors. Both studies gave us unexpected
results. The analysis of VIP protein in RSV-SR transformed
cells showed that VIP was also up-regulated (9 fold) at the level
of protein in transformed cells compared to the control cells that
were infected with RSV-SR-td106. However, normal CEFs
produced VIP at the level similar to that detected in v-src
transformed cells (Fig. 2). We concluded that RSV-SR-td106
virus repressed the transcription of the VIP gene. The VIP we
detected was around 52 kDa, more than twice the size of the
prepro-VIP predicted from the coding sequence of the chicken
and human gene. The monoclonal antibody recognized the
same size 52 kDa protein in the chicken and human brain (data
not shown). It is possible that the VIP gene product detected in
CEFs and in the brain represents a non-processed and non-
secreted form of the hormone or may encode a new VIP
paralog.
Staining of 12 colon carcinomas and 13 breast carcinoma
biopsies identified tumor tissues with clear immunoreactivity
for src Tyr-416 phospho-specific antibodies (8 in colon
adenocarcinoma and 9 in breast carcinoma), yet none of the
25 biopsies showed staining for VIP (Jianhui Shi, Fan Lin and
Conrad Schuerch, unpublished data). As expected, the VIP
antibody showed staining in ganglion cells residing in normal
sections of colon.
General concerns and concluding remarks
The aim of our study was to survey transcriptional changes
affected by RSV and its transforming gene, v-src, in primarycultures of CEFs. Apart from the basic insight into the process
of transformation, we wanted to identify robustly changed
transcripts that could serve as cancer biomarkers. Several genes
that were not previously known as transcripts changed in
transformed cells or sarcomas were identified. Among them is
FST, a hormone-like substance whose protein level could be
monitored in human blood.
Two other studies reported analysis of v-src-affected genes
(Malek et al., 2002; Paz et al., 2004). However, both analyses
used a xenogeneic system of chicken v-src that was over-
expressed in established rodent cell lines, 3Y1 and NIH3T3
lines. Both studies used cells selected with the aid of antibiotic
resistance genes for src expression, following transfection. In
addition, the arrays used in the studies contained a limited
number of genes (8900 human genes in Malek et al. report; and
Fig. 2. Immunoblot analysis of VIP in normal and RSV-SR transformed CEFs.
Upper three-partite panel, top panel (lanes A–G): Western blot analysis of cell
lysates from CEFs (lane A), CEFs infected with RSV-SR td106 mutant (lanes
B–D), and CEFs transformed by RSV-SR (lanes E–G). The blot was probed
with a monoclonal antibody raised against human VIP. Lysates from cells
derived from three independent experiments (infection with RSV-SR td106
mutant and transformation with RSV-SR) were used. Arrow points to VIP of
52 kDa molecular weight. Middle panel, the same Western blot was probed with
src phospho-Tyr 416-specific antibody. Arrow points to c-src of 60 kDa
molecular weight. Lower panel, Coomassie blue staining of the parallel SDS–
polyacrylamide gel analyzed in the upper panels. Lower two panels, top panel
(lanes H–O): Western blot analysis of conditioned media from normal and RSV-
SR transformed CEFs; lane H, lysate from normal, uninfected CEFs that serves
as a positive control for the presence of VIP; lanes I–K, supernatant from CEFs
infected with RSV-SR td 106 mutant; and lanes M–O, supernatant from CEFs
transformed with RSV-SR. Arrow indicates VIP migrating at the apparent
52 kDa molecular weight. Lower panel, Coomassie blue staining of the parallel
SDS–polyacrylamide gel analyzed in the upper panel.
15Rapid Communication12,000 mouse sequences in which 6000 were non-annotated
ESTs in Paz et al. report). Moreover, one of the two studies
documented a concordance between transcripts that were
present in src transformed 3Y1 cells and human tumors, but
did not show direct changes between v-src transformed and
non-transformed 3Y1 cells (Malek et al., 2002). Because ofthese factors, it is difficult to compare the transcriptional
fingerprint of v-src transformation of CEFs that we generated to
that reported previously in rodent cells, especially in the
selected set of 20 robustly modulated genes. With the exception
of one robustly down-regulated gene that encodes LIM protein
1 (FHL1), which was also identified by Paz and colleagues (Paz
et al., 2004), the remaining 19 genes we reported here (Table 1)
were not scored in previous array screens.
We also identified the less robust changes in v-src affected
transcripts (Supplementary Table A) and consider them
important for the understanding of transformation fingerprint.
Small changes (two to three fold modulation) in the transcrip-
tion of genes that encode regulatory proteins or transcription
factors per se could result in unregulated signaling and
contribute to the transformation process (Vogt, 2001). The 3-
fold up-regulation of jun and myc transcripts was recorded in
the array screen. Small changes in the level of transcripts
encoding proteins that act in the same pathway could produce
synergistic responses. The best example in our data is
represented by vascular endothelial growth factor (VEGF) and
ribosomal protein S6 kinase. These two genes are up-regulated
3 fold each and their protein products participate in the mTOR
pathway (Klos et al., 2006). In RSV-SR transformed CEFs, the
level of VEGF gene product is additionally increased by
ribosomal protein S6 kinase, which enhances translation of
VEGF RNA. The resulting synergy between the two up-
regulated gene products may contribute significantly to
angiogenesis and metastasis of v-src induced tumors. Similarly,
we confirmed the up-regulation of Eps8 transcript, whose
protein serves as a substrate of v-src kinase (Gallo et al., 1997).
The concerted action of v-src and Eps8 should contribute to
signals stimulating cell growth.
The transcriptional fingerprint of RSV transformation
reported here represents a static and limited view of the
transformation process. We have isolated total RNAs from cells
that were fully transformed or infected. The cells were harvested
soon after they reached complete transformation, as judged by
visual inspection. To generate a dynamic picture of transcrip-
tional changes caused by v-src, it would be necessary to use
temperature-sensitive mutants of RSV. It is likely that certain
genes are only modulated at the initial and narrow window of
time just when the threshold of transformation by v-src is
reached (Jakobovits et al., 1984; Jahner and Hunter, 1991). It
would also be important to look at genes modulated in RSV
transformed cells that were propagated for longer periods of
time, allowing adaptation and the epigenetic changes that must
occur in spontaneous cancer. Such experiments would allow us
to differentiate between genes that are primary targets of v-src-
induced nuclear signaling pathways and genes that are
modulated by the subsequent wave of “secondary” events.
Finally, to obtain a more complete picture of transformation,
one should connect the repertoire of changed genes with the
signaling network of src as a protein-tyrosine kinase (Blume-
Jensen and Hunter, 2001; Feng et al., 2006).
In our survey, we confirmed two out of nine v-src-induced
genes that were identified in rat fibroblasts transformed by
RSV LA23 temperature sensitive mutant (Chen et al., 1977:
16 Rapid CommunicationJahner and Hunter, 1991). These two genes were rhoB and
ornithine decarboxylase. In our assay, both transcripts were
elevated only two fold in transformed cells and therefore were
excluded from the ‘stringent’ list of 811 genes. An interesting
observation should be noted here. In rat fibroblasts, v-src
induced a gene, which encoded tissue factor. We did not
observe the induction of the tissue factor transcript in CEFs,
although its probe was present and detected in the array. We
did, however, record the repression of tissue factor pathway
inhibitor (see Table 1). This single observation could be an
example of v-src “resourcefulness” in transforming fibroblasts
of different species. Src does this by targeting different
regulators of the same pathway to achieve the same final
“read-out”. Host-specific differences in signaling by src in
chicken versus rodent cells were well documented in the past,
and our study further supports this phenomenon (e.g., Hirai
and Varmus, 1990).
Interleukin 8 (9E3) and gravin are two genes modulated in
RSV transformed cells (Sugano et al., 1987; Bedard et al., 1987;
Frankfort and Gelman, 1995). These genes were also scored for
in our arrays and their transcripts changed as reported
previously, yet the fold changes that we observed were below
the two and a half fold cut off.
There are three concerns which need to be addressed in
future studies. First, it is important to stress that the mRNA
levels do not always correlate with the protein levels (e.g., Tian
et al., 2004). Therefore, one needs to show that changes in the
level of transcript, which we report here, correspond to changes
in the level of protein. Second, the primary culture of chicken
embryo fibroblasts is known to also contain small numbers of
additional cell types that may respond differently to the RSV
infection. The presence of small numbers of myoblasts,
neurons, epithelial and perhaps stem cells that ‘contaminate‘
the dominant population of fibroblasts may be responsible for
detection of transcripts which seem uncommon for fibroblasts
(e.g., nestin). The use of immortalized CEF cell lines such as
DF-1 and SC-1 may not provide the best solution to the
problem, as these cells have unique, immortalization- and
transformation-related changes reflected in the transcription of
mitochondria-encoded genes (DF-1) or alterations in the p53
and Rb pathways (SC-1) (Kim et al., 2001; Christman et al.,
2005). Third, our control virus containing v-src deletion (RSV-
SR-td106) showed strong activity in repressing the VIP gene in
CEFs. Other v-src-regulated transcripts could also have been
affected by the non-transforming virus; therefore, one should
use the primary, non-infected CEFs to control for such a
possibility.
In summary, we have identified and confirmed a set of
twelve new genes that are highly induced (seven) or repressed
(five) in Rous Sarcoma Virus transformed primary chicken
embryo cells, compared to cells infected with the control virus
with deleted src gene. The quantitative changes and the
function of the modulated genes should help us in better
understanding the molecular mechanism of oncogenic transfor-
mation, which for v-src oncogene is characterized by dramatic
neoplastic changes of primary cells and high malignancy of
resulting tumors. Despite the significant phylogenetic distanceof 310 million years between birds and mammals (Burt, 2005),
and examples of species-specific differences in signaling
between certain orthologs (Van Dyke and Jacks, 2002;
Vogelstein and Kinzler, 2004), the human homologues of at
least some of the v-src-modulated chicken genes could
represent biomarkers of human cancers (Russello and Shore,
2004; Homsi et al., 2007).
Materials and methods
Cells, viruses, and preparation of RNA
Chicken embryo fibroblasts (CEFs) were prepared and
maintained as previously described (Hanafusa, 1969). Three
sets of CEFs were infected with high-titer stocks of two viruses.
Half of the plates were infected with the transforming,
oncogenic virus — Schmidt-Ruppin strain of RSV subgroup
A (RSV-SR). The other half were infected with the non-
transforming derivative of RSV-SR named td106, in which the
src gene was deleted (Wang et al., 1984). Both sets of cells were
propagated in parallel under standard conditions. When RSV-
SR CEFs showed complete morphological transformation
(Hanafusa, 1969), the total RNA from the transformed cells
and from the control cells infected with td106 RSV-SR was
isolated using Qiagen Rneasy Minikit. The RNA was isolated
from sub-confluent cultures to ensure that differences in the
growth rate between normal and transformed cells were not
affected by contact inhibition of normal, confluent CEFs. Yield
and quality of RNA were determined through measurement of
the absorbance at 260 nm and 280 nm. All of the RNAs used in
the experiments had a 260/280 ratio of 1.9 or higher. These
preparations of total RNA served as the template for cDNA
synthesis and subsequently for the generation of biotinylated
cRNA probes that were used directly in the hybridization to
Chicken GeneChip® Genome Arrays [Lot # 4009764 and
4017168] (Affymetrix, Inc., Santa Clara, CA).
Microarray analysis
For each chip, 5 μg of RNA was used to synthesize cDNA
with an oligo-dT primer attached to a sequence of the T7
promoter region. An in vitro transcription reaction was used to
generate biotin-labeled cRNA from the cDNA. The cRNAwas
fragmented and an agarose gel was run to verify the sizes of the
RNA fragments. A hybridization cocktail was then prepared
using 20 μg of the fragmented cRNA. The cocktail was
hybridized to a Chicken GeneChip® Genome array at 45 °C for
18 h. Next, the cocktail was removed and the arrays were
washed and incubated with R-Streptavidin-Phycoerithrin
(Molecular Probes, Eugene, OR) following the protocol
supplied by the manufacturer. The signal was amplified using
a biotinylated antibody raised against streptavidin (Vector
Laboratories, Burlingame, CA). The arrays were then washed,
stained, and scanned following standard Affymetrix protocols.
Each total RNA preparation and its derived cRNA was used to
probe one array, giving rise to three experimental values for
each chicken transcript that hybridized with the probe. The
17Rapid Communicationresults were analyzed with the Affymetrix GeneChip Operating
Software 2.1 and Spotfire Decision Site 8.1.
Data analysis
Affymetrix GeneChip Operating Software 2.1 (GCOS)
standard adjustments for artifacts, noise, and background were
used to calculate a detection p-value, detection call, and signal
for each gene on each array. The entire data set was imported
into Microsoft Excel where it was sorted by the detection call.
All gene probes scoring a present or marginal on two or more of
the arrays in each group were selected for further analysis.
These data were imported into Spotfire Decision Site 8.1 where
the first analysis was completed. The data set was normalized
by scaling each experiment by mean, followed by z-score
calculation of the gene probes. The resulting data were then
analyzed using a one-way analysis of variance (ANOVA) test to
determine which genes were significantly changed. A p-value
of≤0.05 was considered significant. The Spotfire Software was
then used to cluster the experiments (columns) and gene probes
(rows) into a heat map using the unweighted average and
Euclidean distance methods. The data were also analyzed using
the Affymetrix GCOS software. This consisted of taking the
original data from each of the three experiments in the entire
data set and comparing them separately. The natural log fold
change for each experiment was calculated using the control as
the baseline. These data were imported to Microsoft Excel,
where the log change was converted to linear change. The final
data set consisted of those genes, which had at least a 2.5 linear
fold change from the GCOS analysis and a p-value of less than
0.05 from the Spotfire analysis.
Quantitative real-time PCR
New total RNAs were prepared from two sets of SR-A-RSV
transformed CEFs and two sets of CEFs infected with SR-A-
RSV td106. Both sets of RNA from each condition were pooled
to make cDNA. The cDNAwas synthesized using 2 μg of RNA,
8 μl of 5× First Strand Buffer (Invitrogen, Carlsbad, CA), 2 μl
of 0.1 M DTT, 1 μl of 50 μM Random Hexamers, 0.8 μl of
25 μM dNTPs, 1 μl of Superscript II RT (Invitrogen, Carlsbad,
CA), and PCR grade water to bring the final volume of each
reaction to 40 μl. PCR conditions were 22 °C for 10 min, 40 °C
for 40 min, 99 °C for 5 min, and 10 °C hold. Quantitative Real-
time PCR (RT-PCR) was performed using Quantitect SYBR
Green PCR kit (Qiagen, Valencia, CA) as per manufacturer-
suggested protocol. A standard curve of serial dilutions (1:1–
1:100,000 of cDNA) and a no template control were included
for each primer pair. RT-PCR analysis was completed using the
second derivative maximum method of Roche Molecular
Biochemicals Light-cycler Software version 3.5 (Roche,
Pleasanton, CA). Using this method, a relative concentration
for each sample was generated based on the standard curve of
the target of interest. This value was then normalized to the
corresponding relative concentration of GAPDH. The resulting
normalized data were further used to determine the change in
expression of each target by taking the ratio of the experimentalvalue to the control value. Sets of 22-mer-long forward [F] and
reverse [R] primers for the chicken GAPDH and the 20
individual transcripts were designed to amplify DNA fragments
below 200 bp long. Integrated DNA Technologies Company
synthesized and provided the oligo-nucleotides. The primers
used in the RT-PCR assay were as follows:
HOUSEKEEPER-GAPDH1-F-AATGCATCGTGCACC-
ACCAACT;
HOUSEKEEPER-GAPDH1-R-TCCCATTCAGCTCAG-
GGATGACTT;
PLAU-F-TGCAACTTGGACTGGGCAAACA;
PLAU-R-TGCAGGGCGTTTCTTGAATGGA;
VIP_F-TGGGAAACAGACTGCCCTTTGA;
VIP_R-AGCATCAGAGTGGCGTTTGACA;
LOC423497_F-ACATTGCCGTGGAAGCACCAAA;
LOC423497_R-AATCTCACCCGTTGGGAAGTGAGT
LOC421581_F-ATCCTGATGTACGCCTGGTTCA;
LOC421581_R-ATTAGGAGAGCAGCAGGCAACT;
LOC423769_F-TTTGGCCAGTATGACTGGTGCT;
LOC423769_R-AACGCTGTTGGGAATGCGGTTT;
LOC421692_F-TGTCTGCATGGCAACAGCATCA;
LOC421692_R-TTGATGAACAGCTGGGTGAGGGAT;
FST_F-TGTGTTTGTGCTCCGGATTGCT;
FST_R-TTTGATCCACCACACACGTGGA;
LOC423890_F-TTGAAGGCTCGTGTTTCGCCTT;
LOC423890_R-TTCAGCAGGATGAAGAAGCCGT;
NES_F-AGCACACCCATTTCCCTTTGGT;
NES_R-AGTGGGAGGGCGATGCTTTATT;
MKP2_F-AAGAAGCGCGTCAAGCTGGAAA;
MKP2_R-AATGGCAGTGTCCGGCACTATT;
NPC2_F-AAGCAGCTGGATAAGAGGGCAT;
NPC2_R-TTGTTGTTCTCCTCCAGTGCCT;
NOV_F-TGCACCAGTGTGCAGACTTACA;
NOV_R-TGAGGACAGCGGAACTCAACTT;
TGFBI_F-GAAGCTTTCCGAGCCATGCCAC;
TGFBI_R-TGGACTTGAGCCGCACAAGAGC;
LOC418180_F-ACGCCGAATGCATCTACACGAA;
LOC418180_R-AGCCAACTTCTCTCATGTGGCA;
LOC428711_F-AAGCAATTGGGTGGGAAGCGTT;
LOC428711_R-TCTTGCAGCCAGCACACTTCTT;
DIO2_F-AAGGGCAACGATGGCAGCAATA;
DIO2_R-TGCACAATGCACACTCGCTCAA;
C1QTNF3_F-ATCAGTTGGCATCTGCTGGCTT;
C1QTNF3_R-TTCTGGAACCTTTGTGGCCAGT;
CPEB1_F-TGCAGCACAAACTAGCCCACAA;
CPEB1_R-ACTGCAGCCAAAGCAGCTTGAT;
TFPI_F-ATGCCATTGCCCTTGGTCTTGA;
TFPI_R-AGTCATCAGTTGCATGCCCAGT;
TGFB3_F-AGAACTGTAATCCAGGAGGCCTGT;
TGFB3_R-TGGGAGCCTTGCAGTTTGCATT.
Immunoblot analysis
Lysates or clarified culture media of uninfected CEFs, of
CEFs infected with RSV-SR mutant td-106, and of CEFs
transformed by RSV-SR were fractionated on 4–20% pre-cast
18 Rapid CommunicationSDS–polyacrylamide electrophoresis iGels (NG11-420 Life
Therapeutics, Australia). Tissues and cells were homogenized
in RIPA lysis buffer containing a cocktail of mammalian
protease inhibitors. Lysates of adult, normal chicken, and
human tissues (brain, colon and intestine) were obtained from
Zyagen Laboratories (San Diego, CA). Lysate samples: were
25 μl/well (CEFs—40 ug, chicken and human tissues—
100 ug); media samples were: 5 μl/well (200 ug). As molecular
weight markers we used Kaleidoscope Prestained Standard
(161-0324 BioRad, Hercules, CA).
Transfer of resolved proteins to nitrocellulose membrane was
monitored by Ponceau red staining. Normalization of proteins
was completed on parallel gels and visualized by staining with
Coomassie Brilliant Blue R250 solution (Bio-Rad Laboratories,
Inc., Hercules, CA) following a standard protocol. After
transfer, lysate proteins on nitrocellulose membranes were
incubated with anti-VIP monoclonal antibody (SC-25347,
Santa Cruz) at 1:200 dilution. The secondary antibody was
peroxidase-labeled anti-mouse (NIF825, Amersham) at 1:5000.
After transfer, media proteins on nitrocellulose membranes were
incubated with anti-VIP (1:100), with peroxidase-labeled anti-
mouse (1:3500). Both blots were then stripped at 65.0 °C for
30 min, washed 2 times for 10 min with TBST containing
0.05% Tween 20, and then blocked 1 h at RT in 5% milk. The
blots were then incubated with anti-phospho-Src antibody (Tyr
416) (2101S, Cell Signaling) at 1:625 dilution followed by the
peroxidase-labeled anti-rabbit secondary antibody (1:10,000).
ECL chemiluminescence kit from Amersham (RPN2108) was
used for detection of proteins on Western blots.
To quantify the relative differences in the expression of
proteins, auto-radiographs of Western blots were scanned using
Imaging System unit from Alpha Innotech. Spot Densitometry
Quantitation Tool program was used.
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